Medication Management in an Octogenarian with Heart Failure and Hypotension
In this actively functioning 80+ year-old man with declining blood pressure (90-100/60-70 mmHg), Imdur (isosorbide mononitrate) should be withdrawn first, followed by dose reduction of bisoprolol if hypotension persists, while maintaining Entresto and apixaban at all costs given their mortality benefits.
Prioritized Medication Adjustment Strategy
First-Line: Discontinue Imdur (Isosorbide Mononitrate)
Nitrates are the most expendable medication in this regimen. They provide symptomatic relief for angina but lack mortality benefit in heart failure and are a common culprit in hypotension 1, 2. The guidelines explicitly state: "If hypotension, first reduce the dose of vasodilators" 1, 2, 3.
- Rationale: Nitrates cause direct vasodilation without improving survival
- Action: Stop immediately
- Expected effect: Blood pressure should stabilize within 24-48 hours
Second-Line: Reduce Bisoprolol Dose (Do Not Discontinue)
If hypotension persists after stopping Imdur, reduce bisoprolol dose by 50% rather than discontinuing 1, 4. Guidelines are explicit: "reduce dose of beta-blockers if necessary, but discontinue only if clearly necessary" 1, 2.
- Critical caveat: Beta-blockers reduce mortality by 34% in heart failure 3
- Symptomatic hypotension is listed as a contraindication, but asymptomatic hypotension is not 4
- In elderly patients (>75 years), beta-blockers remain beneficial despite limited specific trial data 1
- The pacemaker protects against bradycardia, making beta-blocker dose reduction safer
Maintain Entresto at All Costs
Entresto (sacubitril/valsartan) must be preserved unless the patient develops cardiogenic shock 5. This is non-negotiable for several reasons:
The FDA label explicitly addresses this scenario: "If hypotension occurs, consider dose adjustment of diuretics, concomitant antihypertensive drugs... If hypotension persists despite such measures, reduce the dosage or temporarily discontinue ENTRESTO. Permanent discontinuation of therapy is usually not required" 5.
Key evidence supporting continuation:
- Recent 2025 consensus specifically addresses low BP in heart failure: patients with systolic BP 95-110 mmHg on Entresto showed BP increases over time rather than decreases, likely reflecting improved cardiac function 6
- In PARADIGM-HF, patients with baseline systolic BP 95-110 mmHg experienced mild BP increases during follow-up 6
- Discontinuing Entresto after asymptomatic hypotension is associated with worse outcomes 7
- The mortality benefit of Entresto is substantial and proven 8
Critical distinction: This patient's BP (90-100/60-70) represents asymptomatic hypotension. He's still playing weekly poker and doing physical therapy three times weekly—clear evidence of maintained functional capacity. The 2025 HFA consensus emphasizes that asymptomatic hypotension should not trigger Entresto discontinuation 6.
Maintain Apixaban
Continue apixaban unchanged. With a pacemaker, this patient likely has atrial fibrillation or another indication for anticoagulation. The stroke prevention benefit far outweighs any theoretical contribution to hypotension (which is minimal).
Practical Management Algorithm
Step 1: Immediate Actions
- Stop Imdur today
- Check orthostatic vital signs (BP supine and standing after 1-3 minutes)
- Assess for symptoms: dizziness, lightheadedness, syncope, or falls
- Review volume status: check for dehydration or excessive diuresis
Step 2: Monitor (Days 1-7)
- Daily home BP monitoring
- Watch for symptomatic hypotension (dizziness, presyncope)
- Continue current doses of Entresto and bisoprolol
- Ensure adequate hydration
Step 3: If BP Remains Low After 1 Week
- If asymptomatic: No further changes needed. This BP may represent improved cardiac output 6
- If symptomatic: Reduce bisoprolol by 50% (e.g., from 5mg to 2.5mg daily)
- Never reduce Entresto first 6, 5
Step 4: Renal and Electrolyte Monitoring
- Check creatinine and potassium within 1 week of any medication changes 3, 5
- Acceptable creatinine increase: up to 50% from baseline or absolute value <265 μmol/L (3.0 mg/dL) 3
- If creatinine rises above this, reduce Entresto dose before discontinuing 3, 5
Critical Pitfalls to Avoid
Pitfall #1: Discontinuing Entresto Prematurely
The most common error is stopping Entresto at the first sign of low BP. The 2025 HFA consensus explicitly states that low BP should not hinder GDMT optimization 6. Recent evidence shows patients with BP 95-110 mmHg often experience BP increases over time on Entresto, reflecting improved cardiac function 6.
Pitfall #2: Treating Asymptomatic Hypotension Aggressively
This patient is functionally active (weekly poker, thrice-weekly PT). Asymptomatic hypotension in heart failure may indicate improved cardiac output rather than inadequate perfusion 6, 7. The 2006 Canadian guidelines note: "Asymptomatic hypotension does not require intervention" 4.
Pitfall #3: Stopping Beta-Blockers Abruptly
Guidelines warn against "major reduction of beta-blocker dose or abrupt withdrawal" 4. The mortality benefit (34% reduction) is too substantial to sacrifice 3. The pacemaker provides protection against symptomatic bradycardia, making beta-blocker continuation safer in this patient.
Pitfall #4: Ignoring the Run-In Period Data
In PARADIGM-HF, 10.4% of patients discontinued during the Entresto run-in period, but those who tolerated it and were randomized derived equal benefit regardless of hypotensive episodes 8. This patient is already tolerating Entresto—don't undo that success.
Special Considerations for the Elderly
The 2007 ESC/ESH guidelines emphasize that age >80 should not prevent appropriate therapy 9. However, they recommend:
- More gradual dose titration (already accomplished in this stable patient)
- Checking orthostatic BP due to increased postural hypotension risk 9
- Recognizing that elderly patients often need multiple drugs, making BP <140 mmHg difficult to achieve 9
This patient's functional status (weekly poker, regular PT) suggests he's tolerating his regimen well despite the BP numbers.
When to Escalate Care
Refer to heart failure specialist if:
- Symptomatic hypotension persists despite medication adjustments
- Creatinine rises >265 μmol/L (3.0 mg/dL) 3
- Potassium >6.0 mmol/L 3
- Signs of end-organ hypoperfusion develop (confusion, oliguria, cool extremities)
- Patient develops cardiogenic shock 4
Summary of Evidence Quality
The recommendations prioritize:
- FDA drug label guidance for Entresto management 5
- 2025 HFA consensus on low BP in heart failure—the most recent and directly applicable guideline 6
- Multiple ESC and Canadian guidelines consistently recommending vasodilator reduction before beta-blocker or RAAS inhibitor adjustment 1, 4, 2, 3, 4
- Recent research showing safety of Entresto continuation in low BP states 10, 8, 11, 7
The evidence strongly supports an aggressive approach to maintaining mortality-reducing medications (Entresto, beta-blockers) while eliminating symptomatic therapies (nitrates) in elderly patients with asymptomatic hypotension.